Accelerate Diagnostics Stock Forecast, Price & News

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics or view top-rated stocks.

How has Accelerate Diagnostics' stock been impacted by Coronavirus?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has decreased by 53.6% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Accelerate Diagnostics.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings results on Tuesday, November, 9th. The medical research company reported ($0.15) EPS for the quarter, beating the Zacks' consensus estimate of ($0.35) by $0.20. The medical research company earned $3.12 million during the quarter, compared to analysts' expectations of $3.51 million. During the same period in the previous year, the firm earned ($0.33) EPS.
View Accelerate Diagnostics' earnings history.

What price target have analysts set for AXDX?

1 equities research analysts have issued 1-year price objectives for Accelerate Diagnostics' shares. Their forecasts range from $9.00 to $9.00. On average, they anticipate Accelerate Diagnostics' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:

• Jack Phillips, President, Chief Executive Officer & Director (LinkedIn Profile)
• Steven Reichling, CFO, Secretary & Chief Accounting Officer (LinkedIn Profile)
• Lawrence Mertz, Senior VP & Head-Research & Development
• Ron Price, Senior VP & Head-Commercial Operations (LinkedIn Profile)
• Gretchen Strohminger, Senior VP, Head-Human Resources & Culture

Who are some of Accelerate Diagnostics' key competitors?

Some companies that are related to Accelerate Diagnostics include Bionano Genomics (BNGO), Singular Genomics Systems (OMIC), Nautilus Biotechnology (NAUT), EyePoint Pharmaceuticals (EYPT), Rapid Micro Biosystems (RPID), Akoya Biosciences (AKYA), IsoPlexis (ISO), Fluidigm (FLDM), Harvard Bioscience (HBIO), Codex DNA (DNAY), Talis Biomedical (TLIS), Precipio (PRPO), Astrotech (ASTC), SeqLL (SQL) and Scientific Industries (SCND).
View all of AXDX's competitors.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Oracle Investment Management Inc. (6.10%), BlackRock Inc. (3.79%), AXA S.A. (2.58%), Griffin Asset Management Inc. (2.04%), Chicago Capital LLC (0.95%) and Geode Capital Management LLC (0.88%). Company insiders that own Accelerate Diagnostics stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics.

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Griffin Asset Management Inc., Two Sigma Advisers LP, AXA S.A., Goldman Sachs Group Inc., Geode Capital Management LLC, Oracle Investment Management Inc., and Rafferty Asset Management LLC. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or view top insider-selling stocks.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, GSA Capital Partners LLP, Thompson Investment Management Inc., Marshall Wace LLP, Cubist Systematic Strategies LLC, SG Americas Securities LLC, Two Sigma Investments LP, and Keebeck Alpha LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Hany Massarany, Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $4.92.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $302.58 million and generates $11.16 million in revenue each year. The medical research company earns $-78.21 million in net income (profit) each year or ($1.25) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 224 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100, via email at [email protected], or via fax at 520-269-6580.